The promise of new technologies and therapies.
Reintgen
Douglas S
DS
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D013677:Medical Laboratory Science / Q000592:standards / Q000639:trends; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011994:Recombinant Proteins; D021701:Sentinel Lymph Node Biopsy / Q000379:methods; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins